Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGC030 in advanced solid tumors
NCT07822399Phase 1Recruiting
- Sponsor
- MacroGenics
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of MGC030 in urothelial carcinoma (UC), colorectal cancer (CRC), gastric cancer (GC) and 2 more (13 cohorts), sponsored by MacroGenics. Primary endpoint: Adverse Events at 2 years. Started Oct 2026; status: recruiting.
02
Drugs
MGC030
03
Conditions
urothelial carcinoma (UC)colorectal cancer (CRC)gastric cancer (GC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07822399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822399.